Results 31 to 40 of about 3,775 (204)
pharma-kritik, 2015 Eine intestinale Infektion mit Clostridium difficile kann zu einer Kolitis und weiteren Darm-Komplikationen führen. Fidaxomicin ist ein neues Antibiotikum, das zur Behandlung einer solchen Erkrankung eingesetzt werden kann, wenn andere Medikamente (Metronidazol, Vancomycin) nicht genügen.
openaire +1 more source
Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus
BMC Medicine, 2020 Background Zika virus (ZIKV) infection is a global health problem, and its complications, including congenital Zika syndrome and Guillain-Barré syndrome, constitute a continued threat to humans.
Jie Yuan +10 more
doaj +1 more source
Antimicrobial Activities of Fidaxomicin [PDF]
Clinical Infectious Diseases, 2012 Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤ 0.001-1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC(90)) of 0.5 μg/mL.
Goldstein, Ellie J. C. +2 more
openaire +2 more sources
Novel Fidaxomicin Antibiotics through Site-Selective Catalysis
, 2020 Fidaxomicin (FDX) is a marketed antibiotic for the treatment Clostridium difficile infections (CDI). Although showing interesting antibacterial properties against many Gram-positive bacteria, the application of this antibiotic is currently limited to ...
Daniel, Schäfle +4 more
core +1 more source
Antibiotics, 2022 In 2021, the American College of Gastroenterology (ACG), the Infectious Diseases Society of America in conjunction with the Society for Healthcare Epidemiology of America (IDSA/SHEA), and the European Society of Clinical Microbiology and Infectious ...
Jordan Jones +4 more
doaj +1 more source
Effect of using fidaxomicin on recurrent Clostridium difficile infection [PDF]
, 2019 Fidaxomicin is a macrocyclic antibiotic licensed for treating Clostridium difficile infection (CDI). In the UK, fidaxomicin is often reserved for severe CDI or recurrences.
Clewer, Victoria +6 more
core +1 more source
Hematology/Oncology and Stem Cell Therapy, 2018 Objective/background: Clostridium difficile infection (CDI) is a potential complication during hematopoietic stem cell transplantation (HSCT), and no specific recommendations exist regarding treatment of CDI in allogeneic SCT patients.
Laura Prohaska +9 more
doaj +1 more source
Canadian Journal of Infectious Diseases and Medical Microbiology, 2023 Background. Clostridioides difficile (CDI) is the most common cause of nosocomial diarrheal infections. Historically, metronidazole was the first-line treatment, but guidelines now indicate oral vancomycin and fidaxomicin as primary antibiotics for ...
Ariana Saatchi +2 more
doaj +1 more source
Semisynthetic Analogs of the Antibiotic Fidaxomicin – Design, Synthesis, and Biological Evaluation
, 2020 The glycoslated macrocyclic antibiotic fidaxomicin (1, tiacumicin B, lipiarmycin A3) displays good to excellent activity against Gram-positive bacteria and was approved for the treatment of Clostridium difficile infections (CDI).
Regina, Berg +9 more
core +1 more source
, 2023 Fidaxomicin (Dificid) is a commercial macrolide antibiotic for treating Clostridium difficile infection. Total synthesis of fidaxomicin and its aglycone had been achieved through different synthetic schemes.
Yiguang Zhu (340294) +13 more
core +1 more source